Chronic inflammatory diseases like asthma and atopic dermatitis continue to pose major treatment challenges, often requiring injectable biologics or broad-spectrum agents with limited durability. This whitepaper explores a breakthrough approach—targeted protein degradation of STAT6—designed to overcome these limitations. By harnessing the power of PROTAC technology, this next-generation strategy offers the potential for oral administration, sustained pathway suppression, and robust efficacy in Th2-driven inflammation.

• Transformative mechanism: Explores STAT6 degradation as a new modality beyond traditional inhibition
• Compelling preclinical evidence: Highlights efficacy in well-established models of asthma and dermatitis
• Oral and durable: Demonstrates potential for low-dose oral dosing with sustained pharmacodynamic effects

Download the full whitepaper to discover how targeted protein degradation is redefining the future of treating chronic inflammatory diseases.